Rheumatoid Arthritis, recent onset arthritis
Conditions
Interventions
Three monthly evalutions of disease activity score and safety. Medication adjustments by ptotocol, based on DAS calculations. If DAS.2.4 medication will be switched to more intensive treatment includi
HP-group:
1. MTX+SSZ+HCQ+1 single dose cortocisteroid intramuscular
2. MTX+SSZ+HCQ+prednisone
3. MTX+prednison.
IP-group:
1. MTX
2. HCQ
3. Prednisone.
LP-group:
1. Naproxen
3.1 singel dose corticosteroids intramuscular.
Sponsors
Erasmus medical Centre Rotterdam
Department of Rheumatologie
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participant of the REACH cohort (patients with inflammatory joint complaints less then 1 year); 2. All patients must at least have one (out of 66) swollen joint.
Exclusion criteria
Exclusion criteria: 1. Definite diagnosis of crystal arthropathy, (post)infective arthritis or autoimmune rheumatic disorder; 2. Previous therapy with DMARD's or corticosteroids; 3. Pregnancy or wish to become pregnant during the study, or childbearing potential without adequate contraception; 4. Concomittant treatment with an other experimental drug; 5. History or presence of malignancy wthin the last five years; 6. Elevated hepetatic enzyme levels (ASAT,ALAT>2times normal value); 7. Thrombopenia150 umol/l.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Functional ability as measured by HAQ and disease activity score (DAS) over time (area under the curve); 2. Progression of radiological joint damage as measured by Sharp/van der Heijde score. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. ACR arthritis core-set; 2. Quality of Life, as measured with, SF-36, EuroQol; 3. Costs. | — |
Contacts
Public ContactJ.M.W. Hazes
Erasmus MC. Afdeling Reumatologie Ee 959 Antwoordnummer 55
Outcome results
None listed